We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Genomic Differences Cause Racial Disparities in Prostate Cancer

By LabMedica International staff writers
Posted on 17 Jun 2021
Prostate cancer is a disease defined by the abnormal growth of cells. More...
These abnormal cells can proliferate in an uncontrolled way and, if left untreated, form tumors which may metastasize or spread to other parts of the body. Prostate cancer (PCa) is the most common solid organ malignancy in men, with 174,650 new diagnoses and 31,620 deaths expected in 2019 in the USA alone.

Effective prognosis and personalized treatment regimens for PCa require identifying tumor-specific genomic factors and events and discovering disease-associated mechanisms. Although previous studies have demonstrated the existence of genomic differences between African-American (AAM) and European-American (EAM) men, the underlying mechanisms driving poor survival in AAM patients are not completely understood.

Urologists at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) and their colleagues analyzed a cohort of 1,152 men, 596 of whom were African American and 556 of whom were European American, and all of whom had undergone radical prostatectomy. Overall, African-American men had higher pre-treatment prostate-specific antigen levels and higher scores indicating increased risk of post-surgery recurrence, emphasizing the more aggressive disease generally found among African-American men.

From post-radical prostatectomy (RP) formalin-fixed paraffin-embedded blocks were submitted for Decipher testing. Submitted tumor tissue included the highest GG with at least 0.5 mm2 of tissue. RNA was extracted using the RNeasy kit (Qiagen, Santa Clara, CA, USA), and cDNA was prepared and amplified using the NuGEN Ovation WTA assay (NuGEN, Redwood City, CA, USA) and hybridized to Human Exon 1.0 ST microarrays (Thermo Fisher Scientific, Carlsbad, CA, USA). Quantitative real-time PCR was analyzed on the CFX384 Touch real-time PCR system (Bio-Rad Laboratories, Hercules, CA, USA).

Comparative analyses between the race groups were conducted at the clinical, genomic, pathway, molecular subtype, and prognostic levels. The EAM group had increased ERG and ETS expression, decreased SPINK1 expression, and basal-like molecular subtypes. After adjusting for confounders, the AAM group was associated with higher expression of CRYBB2, GSTM3, and inflammation genes (IL33, IFNG, CCL4, CD3, ICOSLG), and lower expression of mismatch repair genes (MSH2, MSH6).

At the pathway level, the AAM group had higher expression of genes sets related to the immune response, apoptosis, hypoxia, and reactive oxygen species. EAM group was associated with higher levels of fatty acid metabolism, DNA repair, and WNT/beta-catenin signaling. The authors concluded that their findings suggest that African-American men who undergo radical prostatectomy should be closely monitored following treatment, as they are generally at increased risk for recurrence. The study was published on June 3, 2021 in the journal Communications Biology.

Related Links:
Icahn School of Medicine at Mount Sinai
Qiagen
NuGEN
Thermo Fisher Scientific
Bio-Rad Laboratories



New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.